BioLabs is where breakthrough molecules come to life.
From idea to vial, we provide a cutting-edge facility for the design, synthesis, and biological testing of novel drug compounds, with a focus on cancer and immune-related diseases. Our modular manufacturing infrastructure is equipped with flow chemistry and microreactor technologies, enabling rapid, safe, and scalable production of small-batch clinical compounds.

Alongside manufacturing, we offer in vitro bioactivity screening services—testing drugs against cell lines, immune cells, and stem cell-derived models to provide robust early-stage efficacy data. Our drug development platform also includes a dedicated effort toward the creation of therapeutic cancer vaccines, representing a promising frontier in targeted, immune-based cancer treatment.

We welcome partnerships with academic researchers, pharmaceutical companies, and emerging biotech firms looking to translate their compounds into real-world therapies—quickly and compliantly, right here in the U.S.

—————————————————————————————————–

Aneel Paulus, M.D., M.S. 

Chief Scientific Officer, TyMe Institute
Chief Operating Officer, TyMe BioLabs and TyMe BioVault

Dr. Aneel Paulus is a distinguished physician-scientist and scientific leader with over 15 years of experience in translational oncology, biobanking, and the development of novel cancer therapeutics from bench-to-bedside. He currently serves as CSO of TyMe Institute, a pioneering private center, focused on early cancer detection, longitudinal monitoring, and personalized prevention. He also serves as COO of BioLabs, the institute’s innovation arm dedicated to drug discovery, therapeutic cancer vaccines, and U.S.-based manufacturing of novel anti-cancer compounds.

At the core of Dr. Paulus’ mission is the integration of individualized biology with next-generation therapeutics—anchored by a state-of-the-art biobank (BioVault) that stores DNA, RNA, immune cells, microbiome, and mitochondria for future regenerative or therapeutic use. Under his scientific and operational leadership as COO, the TyMe Institute is building a seamless ecosystem in which biospecimens inform risk, data guides prevention, and personal biology drives the creation of new treatments.

Dr. Paulus previously served as Director of the Mayo Clinic Multiple Myeloma SPORE Biobank in Jacksonville, Florida, where he led the collection, processing, and preservation of biospecimens for national clinical trials and translational studies. This experience forms the foundation of his work in building BioVault into a future-ready biobank platform for precision prevention and therapeutic regeneration.

During his tenure at Mayo Clinic, Dr. Paulus led a multi-disciplinary translational research team focused on mature B-cell malignancies and novel therapeutic agents. His work contributed to the development and clinical integration of breakthrough drugs including Lenalidomide, Venetoclax, and Ibrutinib, and explored natural compound synergies involving agents like Curcumin and Azadirachta indica (Neem). He has played a key role in designing and executing early-phase clinical trials, bridging preclinical innovation with patient-centered applications.

Dr. Paulus holds an MD from Windsor University and an MS in Interdisciplinary Sciences and Translational Oncology from the State University of New York at Buffalo/Roswell Park Cancer Institute. He has served on international grant review panels and consulted for a range of biopharmaceutical companies, from Fortune 500 leaders (GSK, BMS, AstraZeneca, Janssen, Takeda) to emerging biotech disruptors like Natera, Ascentage, and Affimed. He currently holds academic and teaching affiliations with Mayo Clinic School of Medicine and University of Florida College of Medicine.

Beyond the lab and boardroom, Dr. Paulus is a champion for wellness, youth mentorship, and mind-body approaches to cancer care. His scientific contributions, patents in individualized cancer vaccines, and passion for integrating technology, biology, and humanity position him as a visionary shaping the future of cancer prevention and personalized therapy.